Addressing severe hypertriglyceridemia (sHTG) remains a clinical challenge due to the inadequacy of current therapeutic options to reduce triglyceride levels and prevent acute pancreatitis. However, the landscape is rapidly evolving as several revolutionary treatments targeting the underlying pathophysiology of sHTG are currently in late stages of development. These emerging therapies are poised to transform care for people living with sHTG and familial chylomicronemia syndrome (FCS). Equipping providers with insights into these emerging therapies is crucial for delivering effective disease management and improving patient outcomes. Join us for a discussion led by hypertriglyceridemia experts, featuring highlights from the American College of Cardiology (ACC) 2024 Scientific Sessions on the latest evidence for novel approaches to the management of sHTG and FCS. You’ll also have the opportunity to visualize the underlying mechanisms of action of these novel therapies through video animation and gain immediate access to a downloadable point-of-care resource to aid you in identifying patients with sHTG and FCS in your own clinical practice.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/new-developments-severe-hypertriglyceridemia-shtg-familial-chylomicronemia
- Start Date: 2024-05-24 05:00:00
- End Date: 2024-05-24 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Ionis - Amount: 75000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all